Accelovance Revenue and Competitors
Estimated Revenue & Valuation
- Accelovance's estimated annual revenue is currently $38.4M per year.
- Accelovance's estimated revenue per employee is $155,000
Employee Data
- Accelovance has 248 Employees.
Accelovance's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP, Quality Assurance | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | CRA Manager | Reveal Email/Phone |
4 | Managing Dir Accelovance China | Reveal Email/Phone |
5 | Senior Clinical Research Associate | Reveal Email/Phone |
6 | Global Oncology Therapeutic Lead | Reveal Email/Phone |
7 | Supervisor | Reveal Email/Phone |
Accelovance Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1090M | 5838 | 8% | $38.4M | $6.3B |
What Is Accelovance?
Accelovance is a niche clinical services company specializing in high patient throughput for vaccine and trials targeting healthy normal subjects, from recruitment through study completion. Accelovance has developed a model to increase the reliability and productivity on Phase I (outpatient) and Phase II-IV trials.
keywords:N/A
N/A
Total Funding
248
Number of Employees
$38.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Accelovance News
Some of the Major Key players profiled in the study are Accenture, Linical Accelovance, Cognizant, Laboratory Corporation of America...
... Market Size, Share 2022: Competitor Strategies & Analysis to 2032 | IQVIA, ITClinical, Accenture, ArisGlobal, Linical Accelovance.
Some of the Major Key players profiled in the study are Accenture, Linical Accelovance, Cognizant, Laboratory Corporation of America...
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $67.1M | 248 | 64% | N/A |
#2 | $95.1M | 266 | -3% | N/A |
#3 | $84.1M | 283 | -1% | N/A |
#4 | $57.1M | 284 | 30% | N/A |
#5 | $77.2M | 289 | 4% | N/A |